These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39138712)

  • 1. Evaluation of in vitro Skin Permeation of Clascoterone From Clascoterone Topical Cream, 1% (w/w).
    Yang Y; Wang J; Wanasathop A; Niu M; Ghosh P; Zidan A; Gu J; Hunt R; Faustino P; Ashraf M; Xu X
    AAPS PharmSciTech; 2024 Aug; 25(6):186. PubMed ID: 39138712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study.
    Mazzetti A; Moro L; Gerloni M; Cartwright M
    J Drugs Dermatol; 2019 Jun; 18(6):563. PubMed ID: 31251549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne.
    Mazzetti A; Moro L; Gerloni M; Cartwright M
    J Drugs Dermatol; 2019 Jun; 18(6):570. PubMed ID: 31251550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clascoterone: First Approval.
    Dhillon S
    Drugs; 2020 Nov; 80(16):1745-1750. PubMed ID: 33030710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clascoterone cream (1%) topical androgen receptor inhibitor for the treatment of acne in patients 12 years and older.
    Gold M
    Expert Rev Clin Immunol; 2021 Apr; 17(4):301-308. PubMed ID: 33616473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.
    Hebert A; Thiboutot D; Stein Gold L; Cartwright M; Gerloni M; Fragasso E; Mazzetti A
    JAMA Dermatol; 2020 Jun; 156(6):621-630. PubMed ID: 32320027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris.
    Eichenfield L; Hebert A; Gold LS; Cartwright M; Fragasso E; Moro L; Mazzetti A
    J Am Acad Dermatol; 2020 Aug; 83(2):477-485. PubMed ID: 32348828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothalamic-Pituitary-Adrenal Axis Response in Patients With Acne Vulgaris Treated With Clascoterone.
    Bhatia N; Eichenfield LF; Mazzetti A; Moro L; Squittieri N; Hebert AA
    J Drugs Dermatol; 2024 Jun; 23(6):433-437. PubMed ID: 38834220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual Article: Clascoterone Cream 1%: Mechanism of Action, Efficacy, and Safety of a Novel, First-in-Class Topical Antiandrogen Therapy for Acne.
    Peterson H; Kircik L; Armstrong AW
    J Drugs Dermatol; 2023 Jun; 22(6):SF350992s7-SF350992s14. PubMed ID: 37276168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Alkhodaidi ST; Al Hawsawi KA; Alkhudaidi IT; Magzoub D; Abu-Zaid A
    Dermatol Ther; 2021 Jan; 34(1):e14609. PubMed ID: 33258536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clascoterone cream (Winlevi) for acne.
    Med Lett Drugs Ther; 2021 Dec; 63(1640):202-204. PubMed ID: 35100239
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase 1 Study to Investigate the Effects of Cortexolone 17α-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity.
    Täubel J; Mazzetti A; Ferber G; Burch W; Fernandes S; Patel A; Spencer CS; Freier A; Graff C; Kanters JK; Camm J
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):572-581. PubMed ID: 33942574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years.
    Piszczatoski CR; Powell J
    Clin Ther; 2021 Oct; 43(10):1638-1644. PubMed ID: 34607697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous Pharmacokinetics of Acyclovir Cream 5% Products: Evaluating Bioequivalence with an In Vitro Permeation Test and an Adaptation of Scaled Average Bioequivalence.
    Shin SH; Rantou E; Raney SG; Ghosh P; Hassan H; Stinchcomb A
    Pharm Res; 2020 Oct; 37(10):210. PubMed ID: 33001286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne.
    Kalabalik-Hoganson J; Frey KM; Ozdener-Poyraz AE; Slugocki M
    Ann Pharmacother; 2021 Oct; 55(10):1290-1296. PubMed ID: 33533262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris.
    Eichenfield LF; Gold LS; Han J; Hebert AA; Mazzetti A; Moro L; Squittieri N; Thiboutot D
    J Drugs Dermatol; 2024 Jan; 23(1):1278-1283. PubMed ID: 38206145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro.
    Rosette C; Agan FJ; Mazzetti A; Moro L; Gerloni M
    J Drugs Dermatol; 2019 May; 18(5):412-418. PubMed ID: 31141847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an in vitro human skin permeation assay to assess bioequivalence of two topical cream formulations containing butenafine hydrochloride (1%, w/w).
    Mitra A; Kim N; Spark D; Toner F; Craig S; Roper C; Meyer TA
    Regul Toxicol Pharmacol; 2016 Dec; 82():14-19. PubMed ID: 27816671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clascoterone: a new topical anti-androgen for acne management.
    Santhosh P; George M
    Int J Dermatol; 2021 Dec; 60(12):1561-1565. PubMed ID: 34242398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Permeation Test (IVPT) for Pharmacokinetic Assessment of Topical Dermatological Formulations.
    Santos LL; Swofford NJ; Santiago BG
    Curr Protoc Pharmacol; 2020 Dec; 91(1):e79. PubMed ID: 32991075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.